Publications of Sven Göbel

Göbel, S., Pelz, L., Silva, C. A. T., Brühlmann, B., Hill, C., Altomonte, J., Kamen, A., Reichl, U., & Genzel, Y. (2024)Production of recombinant vesicular stomatitis virus-based vectors by tangential flow depth filtrationApplied Microbiology and Biotechnology, 108 (1), 240doi: 10.1007/s00253-024-13078-6.

Göbel, S., Jaén, K. E., Dorn, M., Neumeyer, V., Jordan, I., Sandig, V., Reichl, U., Altomonte, J., & Genzel, Y. (2023)Process intensification strategies toward cell culture‐based high‐yield production of a fusogenic oncolytic virusBiotechnology and Bioengineering, 120 (9), 2639–2657doi: 10.1002/bit.28353.

Göbel, S., Jaén, K. E., Fernandes, R. P., Reiter, M., Altomonte, J., Reichl, U., & Genzel, Y. (2023)Characterization of a quail suspension cell line for production of a fusogenic oncolytic virusBiotechnology and Bioengineering, 120, 3335–3346doi: 10.1002/bit.28530.

Göbel, S., Kortum, F., Chavez, K. J., Jordan, I., Sandig, V., Reichl, U., Altomonte, J., & Genzel, Y. (2022)Cell-line screening and process development for a fusogenic oncolytic virus in small-scale suspension culturesApplied Microbiology and Biotechnology, 106, 4945–4961doi: 10.1007/s00253-022-12027-5.

Gränicher, G., Babakhani, M., Göbel, S., Jordan, I., Marichal-Gallardo, P., Genzel, Y., & Reichl, U. (2021)A high cell density perfusion process for Modified Vaccinia virus Ankara production: process integration with inline DNA digestion and cost analysisBiotechnology and Bioengineering, 118 (12), 4720–4734doi: 10.1002/bit.27937.

Göbel, S., Pelz, L., Reichl, U., & Genzel, Y. (2023)Upstream processing for viral vaccines - Process intensificationBioprocessing of Viral Vaccines137–174.

Pelz, L., Göbel, S., Jaen , K., Reichl, U., & Genzel, Y. (2023)Upstream processing for viral vaccines – General aspectsBioprocessing of Viral Vaccines79–136.

Göbel, S., Dorn, M., Jaén Chavez, K., Jordan, I., Sandig, V., Altomonte, J., Genzel, Y., & Reichl, U. (2022)Production of a fusogenic oncolytic rVSV-NDV virus in perfusion processesIn: Proceedings Vaccine Technology VIII, 60.

Göbel, S., Pelz, L., Behrendt, I., Prömmel, M., Altomonte, J., Anderlei, T., Bürgin, T., Genzel, Y., & Reichl, U. (2022)Scale-Down of an Ortbital Shaken Bioreactor: High Cell Density Cultivation in Perfusion Mode and Virus productionIn: Proceedings Single-Use Technologies V: Building the Future, 40.

Genzel, Y., Zinnecker, T. M., Göbel, S., & Reichl, U.Intensified cell-based virus production: A process development challenge for multiple cell-virus combinationsPresented at: 16^th PEACe ConferenceSitges (Spain), September 24, 2023.

Genzel, Y., Zinnecker, T. M., Göbel, S., & Reichl, U.Next-Generation Virus Production: From Clone, to AMBR, to Perfusion and Very High Virus YieldPresented at: International Society for Vaccines (ISV) Annual CongressLausanne (Switzerland), October 22, 2023.

Genzel, Y., Zinnecker, T. M., Göbel, S., & Reichl, U.Increase in supply through use of new technologies for high yield vaccinesPresented at: Flanders VaccineBrussels (Belgium), November 12, 2023.

Göbel, S., Dallmeier, K., Jordan, I., de Jong, J. D., Reichl, U., & Genzel, Y.Intensified production for a yellow fever - ZIKA virus vaccine candicatePresented at: Democratization of biotherapies: new manufacturing modalities and intensification'sOxford, UK, June 21, 2023.

Göbel, S., Jaén, K. E., Pelz, L., Reiter , M., Altomonte, J., Reichl, U., & Genzel, Y.Intensifiying OSB processes for high titer virus productionPresented at: 5^th large scale meeting: Orbital shaken bioreactorsGirona (Spain), June 5, 2023.

Göbel, S., Pelz, L., Behrendt, I., Prömmel, M., Altomonte, J., Anderlei, T., Bürgin, T., Genzel, Y., & Reichl, U.Scale-Down of an Ortbital Shaken Bioreactor: High Cell Density Cultivation in Perfusion Mode and Virus productionPresented at: Single-Use Technologies V: Building the FutureMarseille, France, March 20, 2022.

Gränicher, G., Göbel, S., Marichal-Gallardo, P., Jordan, I., Sandig, V., Genzel, Y., & Reichl, U.Integrated cell-culture based MVA virus production process with perfusion mode for vaccines or gene therapyPresented at: Value through intensified bioprocessing IIOxford, United Kingdom, June 22, 2022.

Gränicher, G., Göbel, S., Marichal-Gallardo, P., Jordan, I., Sandig, V., Genzel, Y., & Reichl, U.Integrated cell-culture based MVA virus production process with perfusion mode for vaccines or gene therapyPresented at: 27th ESACT MeetingLisbon (Portugal), June 26, 2022.

Göbel, S., Dorn, M., Jaén Chavez, K., Jordan, I., Sandig, V., Altomonte, J., Genzel, Y., & Reichl, U.Production of a fusogenic oncolytic rVSV-NDV virus in perfusion processesPresented at: Vaccine Technology VIIISitges (Spain), June 12, 2022.

Göbel, S., Jordan, I., Sandig, V., Altomonte, J., Genzel, Y., & Reichl, U.Towards the production of a fusogenic oncolytic rVSV-NDV virus in perfusion modePresented at: 27th ESACT MeetingLisbon (Portugal), June 26, 2022.

Göbel, S., Kortum, F., Jaén Chavez, K., Jordan, I., Sandig, V., Altomonte, J., Genzel, Y., & Reichl, U.Production of a fusogenic oncolytic VSV-NDV virus: cell-line screening and process development in small-scale suspension culturesPresented at: Advancing Manufacture of Cell and Gene Therapies VIICoronado, CA (USA), February 6, 2022.